Lv1
74 积分 2023-05-02 加入
FRI-112 Local control and survival after stereotactic body radiotherapy for hepatocellular carcinoma without macrovascular invasion
4小时前
求助中
FRI-112 Local control and survival after stereotactic body radiotherapy for hepatocellular carcinoma without macrovascular invasion
8小时前
求助中
Mechanisms of inflammatory responses to radiation and normal tissues toxicity: clinical implications
1个月前
已完结
低频超声清创仪治疗糖尿病足慢性溃疡的疗效观察
1个月前
已完结
Radiosensitization Strategies for Hepatocellular Carcinoma: Mechanisms, Therapeutic Advances, and Clinical Perspectives
1个月前
已完结
Metformin increases the radiosensitivity of non-small cell lung cancer cells by destabilizing NRF2
1个月前
已完结
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
1个月前
已完结
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
1个月前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
1个月前
已完结
皖公网安备34019202002308
